Results 61 to 70 of about 74,341 (223)

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

Indian Journal of Medical and Paediatric Oncology, 2017
Introduction: BCR-ABL1 kinase domain mutations represent the most frequent mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%–50% of imatinib-resistant patients with chronic myeloid leukemia in chronic phase (CML-CP)
Puligundla Krishna Chaitanya, Karnam Ashok Kumar, Bala Stalin, Gundeti Sadashivudu, Maddali Lakshmi Srinivas   +4 more
doaj   +1 more source

Nephrogenic Systemic Fibrosis: A Rare Contemporary Case After a Decade of Declining Incidence

JEADV Clinical Practice, EarlyView.
ABSTRACT Nephrogenic systemic fibrosis (NSF) is a rare fibrosing disorder associated with exposure to gadolinium‐based contrast agents in patients with renal impairment. Although its incidence has markedly declined since the restriction of high‐risk linear gadolinium agents, sporadic cases may still occur.
Marta Sánchez Díaz, Alberto Andamoyo Castañeda, Pedro José Navarro Guillamón, Elena Gallego Domínguez, Jorge Alonso Suárez Pérez, Enrique Herrera Acosta   +5 more
wiley   +1 more source

Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib

Turkish Journal of Hematology, 2011
Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice. Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity.
Semra Paydaş, Berna Bozkurt Duman, Melek Ergin   +2 more
doaj   +3 more sources

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Jørgensen, Heather G., Jorgensen, Heather G., Tessa L. Holyoake, Heather G. Jørgensen, Elliott, Moira A., Scobie, Linda, Crossan, Claire, Hatziieremia, Sophia, Zhou, Peixun; id_orcid, Elliott, Moira A, Sophia Hatziieremia, Michie, Alison M, Holyoake, Tessa L., Holyoake, Tessa L, Jørgensen, Heather G, Alison M. Michie, Halbert, Gavin W., Linda Scobie, Gavin W. Halbert, Moira A. Elliott, Claire Crossan, Michie, Alison M., Peixun Zhou, Halbert, Gavin W, Zhou, Peixun   +24 more
core   +1 more source

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

Proteomes, 2014
Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases.
Katerina Arvaniti, Anastasia Papadioti, Maria Kinigopoulou, Vassiliki Theodorou, Konstantinos Skobridis, Georgios Tsiotis   +5 more
doaj   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

Imatinib and hypophosphatemia: Case report and review of literature

Journal of Oncological Sciences, 2017
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Inhibin βB Mediates Oligotrophic Adaptation via Regulating Muscle Satellite Cell Proliferation and Differentiation in Schizopygopsis younghusbandi

Integrative Zoology, EarlyView.
① Nutrient deficiency upregulates inhibin βB, activating SMAD signaling to promote p21. Increased p21 inhibits mcm2/mcm4/mcm5 and cyclin E2, inducing G1‐phase arrest, slowing growth, and reducing energy consumption. ② Inhibin βB also upregulates pdgf‐c, which induces α‐SMA, leading to muscle satellite cell fibrosis.
Weiqiang Li, He Gao, Chaowei Zhou, Luo Lei, Junting Li, Chao Ma, Zitu Ma, Mengwei Yao, Kexin Ma, Yunpeng Xiang, Yan Zhou, Yongrui Lu, Da Ji, Minghong Wei, Luohao Xu, Zhaofang Han, Haiping Liu   +16 more
wiley   +1 more source

RNA profiling and immunohistochemistry analyses of circRNAs in imatinib-resistant gastrointestinal stromal tumors

Journal of Translational Medicine
Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal sarcomas of the upper digestive tract. Imatinib is the first-line therapy for patients with metastatic or unresectable GISTs.
Hanxing Tong, Ning Jia, Wenyang Li, Jingjing Xu, Qiuyue Li, Xiaomeng He, Huaqin Sun, Christopher Corpe, Jin Wang   +8 more
doaj   +1 more source